Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy

Qian Xie, Yanli Su, Karl Dykema, Jennifer Johnson, Julie Koeman, Valeria De Giorgi, Alan Huang, Robert Schlegel, Curt Essenburg, Liang Kang, Keiichi Iwaya, Shuhji Seki, Sok Kean Khoo, Boheng Zhang, Franco Buonaguro, Francesco M. Marincola, Kyle Furge, George F. Vande Woude, Nariyoshi Shinomiya

Research output: Contribution to journalArticlepeer-review

Abstract

Hepatitis B virus (HBV) is a well-known cause of hepatocellular carcinoma (HCC), but the regulators effectively driving virus production and HCC progression remain unclear. By using genetically engineered mouse models, we show that overexpression of hepatocyte growth factor (HGF) accelerated HCC progression, supporting the genomic analysis that an up-regulated HGF signature is associated with poor prognosis in HBV-positive HCC patients. We show that for both liver regeneration and spontaneous HCC development there is an inclusive requirement for MET expression, and when HGF induces autocrine activation the tumor displays sensitivity to a small-molecule Met inhibitor. Our results demonstrate that HGF is a driver of HBV-induced HCC progression and may serve as an effective biomarker for Met-targeted therapy. MET inhibitors are entering clinical trials against cancer, and our data provide a molecular basis for targeting the Met pathway in hepatitis B-induced HCC.

Original languageEnglish
Pages (from-to)247-260
Number of pages14
JournalGenes and Cancer
Volume4
Issue number7-8
DOIs
Publication statusPublished - Mar 2013

Keywords

  • hepatitis B
  • hepatocellular carcinoma
  • hepatocyte growth factor
  • MET
  • targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Fingerprint Dive into the research topics of 'Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy'. Together they form a unique fingerprint.

Cite this